255 related articles for article (PubMed ID: 34165361)
21. Lichenoid rash: A new side effect of oral Cladribine.
Aruta F; Iovino A; Costa C; Manganelli F; Iodice R
Mult Scler Relat Disord; 2020 Jun; 41():102023. PubMed ID: 32146431
[TBL] [Abstract][Full Text] [Related]
22. An update on cladribine for relapsing-remitting multiple sclerosis.
Holmøy T; Torkildsen Ø; Myhr KM
Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
[TBL] [Abstract][Full Text] [Related]
23. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
24. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C
Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
26. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
[TBL] [Abstract][Full Text] [Related]
28. Eyebrow alopecia associated with cladribine treatment for multiple sclerosis.
Budimkic MS; Ivanovic J; Momcilovic N; Mesaros S; Drulovic J
Neurol Sci; 2023 Oct; 44(10):3735-3736. PubMed ID: 37249666
[No Abstract] [Full Text] [Related]
29. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
31. Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
Deana C; Bagatto D; Battezzi A; Pecori D; Lorenzut S; Tuniz F
J Neurol; 2022 Aug; 269(8):4557-4559. PubMed ID: 35352170
[No Abstract] [Full Text] [Related]
32. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Schmidt S
Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
34. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
[TBL] [Abstract][Full Text] [Related]
35. Severe skin reactions associated with cladribine in people with multiple sclerosis.
Mateo-Casas M; Reyes S; O'Toole EA; De Trane S; Yildiz O; Allen-Philbey K; Mathews J; Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2020 Aug; 43():102140. PubMed ID: 32454296
[TBL] [Abstract][Full Text] [Related]
36. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Seferoğlu M; Ethemoğlu Ö; Turan ÖF; Siva A
Neurol Sci; 2021 Sep; 42(9):3533-3535. PubMed ID: 34165650
[TBL] [Abstract][Full Text] [Related]
37. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
[TBL] [Abstract][Full Text] [Related]
38. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Meuth SG; Ruck T; Aktas O; Hartung HP
Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
40. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
